Upload
others
View
1
Download
0
Embed Size (px)
Citation preview
© CELLO HEALTH PLC
February 2019
© CELLO HEALTH PLC 2
CELLO HEALTH PLC
MISSION
To build a world-class, healthcare-focused marketing and scientific commercial advisory company.
• 1,000 professionals delivering gross profit of £100m+
© CELLO HEALTH PLC 3
CELLO HEALTH PLC
FULL YEAR TRADING UPDATE - 17 JANUARY 2018
• Overall, delivery on market consensus for 2018
• Strong trading by Cello Health
• Flat trading from Cello Signal
• Net cash at year end, with strong cash flows in H2
• Growing dividend
• Strong organic growth story, complemented with targeted acquisitions
• Focus on organic start-ups
© CELLO HEALTH PLC 4
CELLO HEALTH PLC
2017 2016Headline
Gross Profit
£m
Headline Operating
Profit£m
Margin %
Headline Gross Profit
£m
Headline Operating
Profit£m
Margin %
Cello Health 60.2 10.6 17.7% 47.6 8.6 18.1%
Cello Signal 41.0 3.9 9.5% 43.6 4.5 10.3%
Sub total 101.2 14.5 14.3% 91.2 13.1 14.4%
Central cost - (2.7) - - (2.6) -
Group 101.2 11.8 11.7% 91.2 10.5 11.5%
HISTORICAL PERFORMANCE
© CELLO HEALTH PLC 5
CELLO HEALTHPLC
• Franchise and Brand Strategy
• Scenario and Competitor Planning
• Launch Excellence
• Forecasting and Valuation
• Asset and Indication Prioritisation
• Commercialisation Strategy
• Business Development
• Analysis and Assessment
• Strategic Communication Planning
• Data Dissemination
• Stakeholder Engagement
• Education and Outreach
• Consumer Engagement
• Landscaping and unmet needs
• Patient Journey
• TPP Optimisation
• Customer and Market Segmentation
• Positioning and Message Development
• Brand Tracking
29% 40%31%2018 Gross profit:
WHAT WE DO
SUPPORTING CLIENTS ACROSS THE PRODUCT LIFECYCLE, WITH A FOCUS ON EARLY DRUG DEVELOPMENT
Pre-clinical Pre-launch Launch Post-launch Brand optimisation
© CELLO HEALTH PLC 6
CELLO HEALTH PLC
One brand, one team• Cello Health brand• BD culture• Marketing out-reach• Events• Uniform bonus scheme
Service innovation• Biotech• E-Village• IQ • Cello Health Logic• Pulsar Health• Signal digital capacity
Global presence• Hub offices in New York,
Pennsylvania, London and Farnham• USA 45% of Cello Health 2018
gross profits• 24 out of 25 top pharmaceutical as
clients
Collaborative culture• Cello Academy• Centres of excellence• Graduate recruitment • Global BD team
A fusion of advisory and delivery capability under one global lead brand across pharmaceuticals, biotech, devices, OTC, social health and charities
SOURCES OF COMPETITIVE ADVANTAGE
© CELLO HEALTH PLC 7
CELLO HEALTHPLC
Client Size• Large: >$10bn in annual
sales (2017)•Mid: Between $2.25bn
and $10bn in sales• Small: <$2.25bn in sales
SOURCES OF REVENUE
© CELLO HEALTH PLC 8
• MSAs with 24 of the top 25 drug producers
• Wide range of US based biotech clients
• Increasing med-tech and devices client base
• Growing consumer health range of clients
• Established public health and health charities client base
CELLO HEALTH PLC
SOURCES OF REVENUE
© CELLO HEALTH PLC 9
CELLO HEALTH PLC
MACRO GROWTH DRIVERS
Pricing pressure
RX CX trend
Growth of orphan drugs and customised medicines
Regulatory and market access changes
Strong R & D/pipelines
Improved diagnostics and unmet needs
Demographics
Outsourcing trend
C. 5% MARKET GROWTH
© CELLO HEALTH PLC 10
CELLO HEALTH PLC
CLIENT SPECIFIC TRENDS
• Orphan propositions increasingly making it direct to market
• Surge in interest in non-standard therapeutic solutions
➢Immunotherapy
• Growing role of ‘real world data’ in verifying efficacy
• Consumer engagement requirements increasing
• Pricing pressure raises need for efficiency in commercial delivery, speed to market and market impact
• New entrants disrupt established models
➢Biosimilars
© CELLO HEALTH PLC 11
CELLO HEALTH PLC
CELLO HEALTH BOARD
LEADERSHIP TEAMSEurope and US
EXPERTISE HUBSCAPABILITY OPERATING
BOARDS
Cello Health Insight
Cello Health Consulting
Cello Health Communications
Forecasting Market AccessBusiness
Development
Rare Diseases Microbiome
MEETING CLIENT NEEDS
© CELLO HEALTH PLC 12
CELLO HEALTH PLC
THE COMPETITIVE LANDSCAPE
• CROs migrating towards ‘soup to nuts’ solutions➢Inventiv + Research Inc = Syneos Health
➢Quintiles + IMS = IQVIA
• Private equity highly active➢Parexel
• Range of emerging consolidators➢UDG
➢EVERSANA
Accelerating consolidation of providers
© CELLO HEALTH PLC 13
CELLO HEALTH PLC
CONSUMER
ENGAGING WITH THE CONSUMER AGENDA
© CELLO HEALTH PLC 14
CELLO HEALTHPLC
• GROWTH
• INNOVATION
• LEVERAGE
STRATEGIC PRIORITIES
© CELLO HEALTH PLC 15
CELLO HEALTH PLC • Digital marketing and social media research solutions for big
corporates
• Blue chip global client base: Healthcare, Technology, Financial Services, Public Sector, Utilities and Charities
• Solid core contracted revenue stream and visibility
• Global office network: Edinburgh, London, Cheltenham, Los Angeles, and Singapore
• Strong technology underpinning and proprietary software licensing model
CELLO SIGNAL
© CELLO HEALTH PLC 16
ResearchDigital and Creative
Communications
Specialist Communication
Services
LBGRBS
NPowerNetwork Rail
RBLIFAWWWF
BUPAThe Scottish Government
EFPIABHF
NovonordiskBRC
TFLTesco
WargamingSonySky
L’OrealDisney
VodaphoneEA
NetflixHP
NovartisAstraZeneca
MerlinMarriott
CELLO HEALTH PLC
CELLO SIGNAL
© CELLO HEALTH PLC 17
Double the size and scale of Cello
Health in the next 3 years
Working across the whole
lifecycle but best known for work
in early drug development
Working at the forefront of
where science and technology is
going
A more integrated Health business where
our fusion of expertise
differentiates
An expanded client base with a
broader definition of
what we mean by health*
*from biopharmaceuticals to Med-Tech, m-Health, devices, wearables to the public (NHS in UK) and private providers, health insurers, health finance or patient advocacy or health charities
CELLO HEALTH PLC
AMBITIONS
© CELLO HEALTH PLC 18
GROWTH IN 2019/20
• Continued addition of professionals, particularly in the US
• Continued expansion in core hubs - New York, Yardley, Farnham and London
• Addition of Philadelphia, Boston and Berlin
• Expansion of Pulsar Health product with Cello Health Logic
• Collaboration with Signal Health to deliver digital communication solutions in US and UK
• Ongoing acquisition programme, with US focus
CELLO HEALTH PLC